Hannah Thrash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hannah Thrash has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Wilson
Department of Pathology, Duke University, Durham, North Carolina
29 shared publications - Carina E. Dagotto
Department of Genetics, Harvard Medical School, Boston, MA, United States
29 shared publications - Gangjun Lei
Department of Surgery, Duke University, Durham, NC, USA
29 shared publications - Herbert Kim Lyerly
Department of Surgery, Division of Surgical Sciences, Duke University Medical Center
29 shared publications - Jason McBane
Department of Surgery, Duke University, Durham, NC, USA
29 shared publications - Joshua C. Snyder
Department of Cell Biology, Duke University Medical Center
29 shared publications
Latest Publications
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating mutant GFP and Luc activity in Adenovirus vaccines
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating mutant GFP and Luc activity in Adenovirus vaccines
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Summary of tumor behavior in differentially tolerant animal models. A, Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily observed with fluorescence/bioluminescence. B, Conversely, in immune-competent animals the presence of foreign immunogens often results in complete rejection of the primary tumor, or severely restricts expression of immunogenic antigens and limits the utility of reporter proteins. C, However, NoGlow mice are tolerant to foreign GFP, Luciferase, and rtTA, thus allowing primary tumor growth and de novo metastasis of xenoantigen-expressing tumor cells.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Summary of tumor behavior in differentially tolerant animal models. A, Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily observed with fluorescence/bioluminescence. B, Conversely, in immune-competent animals the presence of foreign immunogens often results in complete rejection of the primary tumor, or severely restricts expression of immunogenic antigens and limits the utility of reporter proteins. C, However, NoGlow mice are tolerant to foreign GFP, Luciferase, and rtTA, thus allowing primary tumor growth and de novo metastasis of xenoantigen-expressing tumor cells.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating the NoGlow construct in vitro
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating the NoGlow construct in vitro
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating mutant GFP and Luc activity in Adenovirus vaccines
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Validating mutant GFP and Luc activity in Adenovirus vaccines
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Tolerance to foreign antigens is animal model specific. A and B, Mice expressing GFP and Luc in the pituitary (GH; n = 5), full-body GFP, and Luc (CAG Luc-GFP; n = 5), in FoxP3+ cells (Foxp3-GFP; n = 4), or wild-type (WT) C57Bl/6 (n = 4) were vaccinated with adenovirus (Ad) encoding GFP/Luc (2.6 × 1010 vp/mouse) and anti-Luciferase (A) or anti-GFP (B) in the serum were evaluated by ELISA after 2 weeks. Only CAG Luc-GFP animals, which express both GFP and Luc, display humoral tolerance to both upon vaccination. P values shown are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C and D, E0771 GFP-Luc cells were implanted into the MFP of female WT C57Bl/6, GH, or CAG Luc-GFP mice (n = 10 each) and subsequently vaccinated with Ad-GFP/Luc or Ad-LacZ as control on day 3 (n = 5/group each). Growth of individual tumors for the duration of the experiment (C) or average tumor volume until time of first euthanasia (D) comparing control or antigen-specific Ad demonstrate that E0771 GFP-Luc cells grow significantly larger in tolerant CAG Luc-GFP mice. P values shown are at day of first euthanasia by two-way ANOVA with Bonferroni multiple comparisons test. E, Female WT (n = 3) or mice expressing human HER2 under the whey acid protein (WAP) promoter (WAP HER2; n = 5) or MMTV Cre–driven CAG promoter (MMTV CAG HER2; n = 3) were vaccinated with Ad-Human Her2 and splenocytes were analyzed for anti-HER2 responses by ELISPOT after 3 weeks. WAP HER2 mice displayed reduced anti-HER2 responses compared with WT animals; however, MMTV CAG HER2 animals produced a limited anti-HER2 T-cell response compared with both WT and WAP HER2. Groups were compared by two-way ANOVA with Tukey multiple comparisons test. F, Doxycycline-inducible GFP animals were given doxycycline (dox)-containing chow at the indicated time points, vaccinated at 9 weeks old, and euthanized after two weeks. G, Serum anti-GFP responses in animals from F reveal that GFP remains highly immunogenic in mice with late (8 weeks old) versus early (4 weeks old/at birth) expression of GFP via doxycycline. P values shown are at 1:50 dilution by two-way ANOVA with Tukey post hoc analysis. All P values represent mean ± SEM.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Tolerance to foreign antigens is animal model specific. A and B, Mice expressing GFP and Luc in the pituitary (GH; n = 5), full-body GFP, and Luc (CAG Luc-GFP; n = 5), in FoxP3+ cells (Foxp3-GFP; n = 4), or wild-type (WT) C57Bl/6 (n = 4) were vaccinated with adenovirus (Ad) encoding GFP/Luc (2.6 × 1010 vp/mouse) and anti-Luciferase (A) or anti-GFP (B) in the serum were evaluated by ELISA after 2 weeks. Only CAG Luc-GFP animals, which express both GFP and Luc, display humoral tolerance to both upon vaccination. P values shown are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C and D, E0771 GFP-Luc cells were implanted into the MFP of female WT C57Bl/6, GH, or CAG Luc-GFP mice (n = 10 each) and subsequently vaccinated with Ad-GFP/Luc or Ad-LacZ as control on day 3 (n = 5/group each). Growth of individual tumors for the duration of the experiment (C) or average tumor volume until time of first euthanasia (D) comparing control or antigen-specific Ad demonstrate that E0771 GFP-Luc cells grow significantly larger in tolerant CAG Luc-GFP mice. P values shown are at day of first euthanasia by two-way ANOVA with Bonferroni multiple comparisons test. E, Female WT (n = 3) or mice expressing human HER2 under the whey acid protein (WAP) promoter (WAP HER2; n = 5) or MMTV Cre–driven CAG promoter (MMTV CAG HER2; n = 3) were vaccinated with Ad-Human Her2 and splenocytes were analyzed for anti-HER2 responses by ELISPOT after 3 weeks. WAP HER2 mice displayed reduced anti-HER2 responses compared with WT animals; however, MMTV CAG HER2 animals produced a limited anti-HER2 T-cell response compared with both WT and WAP HER2. Groups were compared by two-way ANOVA with Tukey multiple comparisons test. F, Doxycycline-inducible GFP animals were given doxycycline (dox)-containing chow at the indicated time points, vaccinated at 9 weeks old, and euthanized after two weeks. G, Serum anti-GFP responses in animals from F reveal that GFP remains highly immunogenic in mice with late (8 weeks old) versus early (4 weeks old/at birth) expression of GFP via doxycycline. P values shown are at 1:50 dilution by two-way ANOVA with Tukey post hoc analysis. All P values represent mean ± SEM.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. A, Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre recombinase. However, in the presence of Cre the stop site is recombined to yield a single transcript encoding rtTA3 and mutant GFP/Luc driven by the CAG promoter. B, Chimeric founder NoGlow animals were crossed to CMV (full-body) Cre animals to test activity and expression of the construct. Representative bioluminescence imaging of female C57Bl/6, CAG Luc-GFP, and F1 CMV Cre NoGlow littermates with or without the NoGlow construct reveal no background bioluminescence in CMV Cre NoGlow+ animals. C, Bioluminescent imaging of representative lungs/livers shows no background bioluminescence in NoGlow+ mice. D, Chromogenic Luciferase staining in livers from NoGlow+ and control mice confirms luciferase protein expression despite the lack of bioluminescence in B and C. E, Representative fluorescent imaging of male C57Bl/6, CAG Luc-GFP, and F1 CMV Cre NoGlow animals shows no background fluorescence in CMV Cre NoGlow+ mice, while immunofluorescent staining (F) for GFP in liver sections from CMV Cre NoGlow+ animals confirms that GFP protein can be detected upon antibody staining.
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. A, Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre recombinase. However, in the presence of Cre the stop site is recombined to yield a single transcript encoding rtTA3 and mutant GFP/Luc driven by the CAG promoter. B, Chimeric founder NoGlow animals were crossed to CMV (full-body) Cre animals to test activity and expression of the construct. Representative bioluminescence imaging of female C57Bl/6, CAG Luc-GFP, and F1 CMV Cre NoGlow littermates with or without the NoGlow construct reveal no background bioluminescence in CMV Cre NoGlow+ animals. C, Bioluminescent imaging of representative lungs/livers shows no background bioluminescence in NoGlow+ mice. D, Chromogenic Luciferase staining in livers from NoGlow+ and control mice confirms luciferase protein expression despite the lack of bioluminescence in B and C. E, Representative fluorescent imaging of male C57Bl/6, CAG Luc-GFP, and F1 CMV Cre NoGlow animals shows no background fluorescence in CMV Cre NoGlow+ mice, while immunofluorescent staining (F) for GFP in liver sections from CMV Cre NoGlow+ animals confirms that GFP protein can be detected upon antibody staining.
- Open Access
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Description of animal models used in the study
- 9 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
Description of animal models used in the study